Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

Yana Dekempeneer; Thomas Cardinaels

doi:10.1021/acs.molpharmaceut.0c00580

Therapeutic Efficacy of ²¹³Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer

Yana Dekempeneer & Thomas Cardinaels · 2020-08-13

Targeted alpha-particle therapy (TAT) might be a relevant therapeutic strategy to circumvent resistance to conventional therapies in the case of HER2-positive metastatic cancer. Single-domain antibody fragments (sdAb) are promising vehicles for TAT because of their excellent

Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer

Links

Journal

Institutions

Authors

Therapeutic Efficacy of ²¹³Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer